Back to All Combinations

Young-Onset CRC (<50)

Intermediate Prognosis
15.00% Prevalence Level 2A Special Populations
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
Multiple
Treatment Implications

Higher hereditary rate. Screen all for Lynch.

Recommended Treatments
MSI/MMR testing
Germline testing
Standard treatment
Treatments to Avoid

No specific contraindications noted

Study References

Early-onset CRC literature

Key Statistics
15.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
All <50 should have genetic evaluation.
Information

Category: Special Populations

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.